Further experiments in TKI-sensitive lung adenocarcinoma cell lines (PC-9 and H1560, which express the D746–750 deletion EGFR mutant, and H1975 that express the L858R mutant) showed that erlotinib dramatically induces the expression of BIM, another pro-apoptotic BH3-only member of the BCL2 family [112], which, like PUMA, also mediates TKI-induced apoptosis via the intrinsic pathway of caspase activation [114] (for a transcriptional profiling of NSCLC cell lines, see [115,116]). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.